CoChat

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Open access
Chen, Alice P., Sharon, Elad, O’Sullivan-Coyne, Geraldine, Moore, Nancy, Foster, Jared C., Hu, James S., Van Tine, Brian A., Conley, Anthony P., Read, William L., Riedel, Richard F., Burgess, Melissa A., Glod, John, Davis, Elizabeth J., Merriam, Priscilla, Naqash, Abdul R., Fino, Kristin K., Miller, Brandon L., Wilsker, Deborah F., Begum, Asma, Ferry-Galow, Katherine V., Deshpande, Hari A., Schwartz, Gary K., Ladle, Brian H., Okuno, Scott H., Beck, Jill C., Chen, James L., Takebe, Naoko, Fogli, Laura K., Rosenberger, Christina L., Parchment, Ralph E., Doroshow, James H. · 2023 · New England Journal of Medicine
Cited by 166

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Alveolar soft part sarcoma (ASPS) is a rare soft-tissue sarcoma with a poor prognosis and no established therapy. Recently, encouraging responses to immune checkpoint inhibitors have been reported. METHODS: We conducted an investigator-initiated, multicenter, single-group, phase 2 study of the anti-programmed death ligand 1 (PD-L1) agent atezolizumab in adult and pediatric patients with advanced ASPS. Atezolizumab was administered intravenously at a dose of 1200 mg (in patients ≥18 years of age) or 15 mg per kilogram of body weight with a 1200-mg cap (in patients <18 years of age) once every 21 days. Study end points included objective response, duration of response, and progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, as well as pharmacodynamic biomarkers of multistep drug action. RESULTS: A total of 52 patients were evaluated. An objective response was observed in 19 of 52 patients (37%), with 1 complete response and 18 partial responses. The median time to response was 3.6 months (range, 2.1 to 19.1), the median duration of response was 24.7 months (range, 4.1 to 55.8), and the median progression-free survival was 20.8 months. Seven patients took a treatment break after 2 years of treatment, and their responses were maintained through the data-cutoff date. No treatment-related grade 4 or 5 adverse events were recorded. Responses were noted despite variable baseline expression of programmed death 1 and PD-L1. CONCLUSIONS: Atezolizumab was effective at inducing sustained responses in approximately one third of patients with advanced ASPS. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT03141684.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2303383

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 166

Metadata

Authors
Chen, A. P., Sharon, E., O’Sullivan-Coyne, G., Moore, N., Foster, J. C., Hu, J. S., Van Tine, B. A., Conley, A. P., Read, W. L., Riedel, R. F., Burgess, M. A., Glod, J., Davis, E. J., Merriam, P., Naqash, A. R., Fino, K. K., Miller, B. L., Wilsker, D. F., Begum, A., Ferry-Galow, K. V., Deshpande, H. A., Schwartz, G. K., Ladle, B. H., Okuno, S. H., Beck, J. C., Chen, J. L., Takebe, N., Fogli, L. K., Rosenberger, C. L., Parchment, R. E., & Doroshow, J. H.
Venue
New England Journal of Medicine
Published
2023-09-07
Volume
389
Issue
10
Pages
911-921
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4386471099
Cited by
166
References
4
FWCI
26.21
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.